GPS2 confers l-asparaginase resistance in acute lymphoblastic leukemia cells through ATF4/ASNS axis
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.G protein pathway suppressor 2 (GPS2) promotes resistance to l-asparaginase (l-ASP) chemotherapy in acute lymphoblastic leukemia (ALL) by stabilizing the ATF4/ASNS pathway. Targeting GPS2 may overcome this resistance.
Area Of Science
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background
- L-asparaginase (l-ASP) is a critical chemotherapy for pediatric acute lymphoblastic leukemia (ALL).
- Resistance to l-ASP is a significant challenge, and its underlying mechanisms require further elucidation.
- Understanding these mechanisms is crucial for improving treatment outcomes in ALL patients.
Purpose Of The Study
- To investigate the role of activating transcription factor 4 (ATF4) and its downstream targets in l-ASP resistance.
- To identify novel regulators involved in the ATF4 pathway that contribute to l-ASP resistance in ALL.
- To explore potential therapeutic strategies targeting these regulators to overcome l-ASP resistance.
Main Methods
- Utilized cell lines and xenograft models of ALL.
- Investigated the interaction between GPS2, ATF4, and BTRC using biochemical assays.
- Assessed the impact of GPS2 knockdown on ATF4/ASNS expression and l-ASP sensitivity in vitro and in vivo.
Main Results
- Activation of ATF4 and its target ASNS is pivotal for l-ASP resistance in ALL cells.
- G protein pathway suppressor 2 (GPS2) stabilizes ATF4 by inhibiting its ubiquitination and degradation via BTRC.
- GPS2 knockdown sensitizes ALL cells to l-ASP and enhances therapeutic efficacy in vivo.
Conclusions
- GPS2 positively regulates the ATF4/ASNS axis, conferring l-ASP resistance in ALL.
- Targeting the GPS2/ATF4/ASNS pathway presents a promising therapeutic strategy to overcome l-ASP resistance.
- These findings offer new insights into the molecular mechanisms of chemotherapy resistance in ALL.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
